HR1921 is a narrow, early-stage bill that would reclassify fully implanted active middle ear hearing devices as prosthetics under Medicare, removing the hearing aid coverage exclusion. The bill has no dollar authorization, minimal legislative momentum (3 cosponsors, referred to committee in March 2025), and no market impact observed. The primary structural beneficiaries are pure-play manufacturers of these implantable devices, namely Enova Medical (ENPH) and Cochlear (COCH), but passage probability is low at this stage.
→ Medicare Part B begins covering the device and implantation procedure; clinics and hospitals are incentivized to offer these procedures due to predictable reimbursement, expanding the total addressable market
HR1921